Stock listing

Scynexis, Inc.

Selected listing: 0L49 · LSE · USD · GB

Scynexis, Inc. (LSE:0L49), Health Technology. Latest release Oct 6, 2026: SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective…

0L49:LSEUSDGBUpdated October 2, 2026

Ticker: LSE:0L49
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: LSE
Currency: USD

Latest news from Scynexis, Inc.

SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

October 6, 2026

SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247

September 28, 2026

SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors

September 22, 2026

SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development

September 15, 2026

SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer

September 10, 2026

All Scynexis, Inc. news →

Events

Replays

SCYNEXIS, Inc. (SCYX) Q3 2022 Earnings Call
Wed, Nov 09, 2022 · 07:30 AM ET
Watch
SCYNEXIS, Inc. (SCYX) Q2 2022 Earnings Call
Mon, Aug 15, 2022 · 08:30 AM ET
Watch
SCYNEXIS, Inc. (SCYX) Q1 2022 Earnings Call
Thu, May 12, 2022 · 08:30 AM ET
Watch

Research Scynexis, Inc.

Scynexis, Inc. company profile

View the public company page for Scynexis, Inc. on 6ix.

Scynexis, Inc. news

Read company news and market updates connected to Scynexis, Inc..

Scynexis, Inc. investor events

Find investor webinars, events, and replay context for Scynexis, Inc..